Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) Sees Large Growth in Short Interest
by Doug Wharley · The Cerbat GemLipella Pharmaceuticals Inc. (NASDAQ:LIPO – Get Free Report) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 50,800 shares, a growth of 215.5% from the November 30th total of 16,100 shares. Currently, 6.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 200,500 shares, the days-to-cover ratio is presently 0.3 days.
Lipella Pharmaceuticals Stock Performance
LIPO traded down $0.17 during midday trading on Friday, hitting $3.15. The stock had a trading volume of 161,839 shares, compared to its average volume of 166,975. Lipella Pharmaceuticals has a 1 year low of $2.21 and a 1 year high of $12.00. The business has a fifty day moving average of $2.93 and a 200 day moving average of $3.57. The company has a market cap of $3.81 million, a P/E ratio of -0.74 and a beta of 0.38.
Lipella Pharmaceuticals Company Profile
Lipella Pharmaceuticals Inc, a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).
See Also
- Five stocks we like better than Lipella Pharmaceuticals
- The How And Why of Investing in Oil Stocks
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Top 3 ETFs to Hedge Against Inflation in 2025
- What is the S&P 500 and How It is Distinct from Other Indexes
- These 3 Chip Stock Kings Are Still Buys for 2025